Report
Hyloris FIRST LOOK: Signs exclusive UK licence and supply agreement for XTRAZA
Hyloris announced that an exclusive licence and distribution agreement has been signed with Colonis Pharma for XTRAZA (tranexamic acid oral rinse) in the UK, where Hyloris will receive undisclosed milestones and will supply the product to Colonis in the UK. A phase 3 trial for the candidate is ongoing in the US and EU, with data previously guided for 1H25, which means the product could reach market in 2026. For reference, we estimate peak sales of € 27m for tranexamic acid oral rinse in the US with € 7m in royalties for Hyloris at peak, and expect the UK to be a fraction of the US market. With no material changes to the business case, we reiterate our € 5 TP and HOLD rating.
Underlying
Hyloris Pharmaceuticals
Provider
KBC Securities
We are a financial services provider for several types of professional clients, each with distinct needs.
Jacob Mekhael
Other Reports on these Companies
Other Reports from KBC Securities
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.